$CYTR fellow shareholders the higher the sp goes, the less we have the risk of a cheap buy out offer. Avoid unnecessary swing trades - we are far below the correct value for cytrx. I would say we should be around the PSS transaction of $6.6 before the Arimoclomol approval. After the approval it should go up by $10 to $16+ pps. Just my opinion, nevertheless avoid to expose us to a unnecessary risk. I know many here a smart enough to understand this problem.